Entero Therapeutics (NASDAQ:ENTO) Stock Price Down 3.4% – What’s Next?

Entero Therapeutics, Inc. (NASDAQ:ENTO)’s share price dropped 3.4% during mid-day trading on Thursday . The company traded as low as $3.33 and last traded at $3.42. Approximately 23,477 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 2,798,922 shares. The stock had previously closed at $3.54.

Entero Therapeutics Trading Down 3.4%

The stock has a market capitalization of $5.43 million, a price-to-earnings ratio of -2.02 and a beta of 1.19. The firm’s fifty day moving average price is $4.72 and its 200 day moving average price is $3.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Entero Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics as of its most recent SEC filing. 12.30% of the stock is owned by institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.